Corvus Pharmaceuticals (CRVS) Study Update summary

Key findings from the Phase I soquelitinib study in atopic dermatitis

• Interim data from the first cohort show a 55.9% mean reduction in EASI score at four weeks and 69.1% at eight weeks, outperforming placebo and comparable to Dupixent historical data.

• 75% of active group patients achieved EASI 50 at four weeks, with durable responses observed after treatment cessation.

• EASI-75 and EASI-90 response rates at eight weeks were 40% and 10% respectively, with 30% achieving IGA 0/1.

• All soquelitinib patients showed EASI improvement, with effects beginning as early as day 8.

• Efficacy was comparable to or exceeded results from Phase 1 and Phase 3 Dupixent trials at similar time points.

Safety and tolerability

• No significant safety issues were observed; only mild nausea and one COVID-19 case, both resolved without dose modification.

• No clinically significant lab abnormalities were reported.

• Safety profile supported by experience in over 100 patients and approximately 9,000 patient-treatment days, some treated for up to two years.

• No adverse events were reported in Cohort 2.

Study design and patient characteristics

• Randomized, double-blind, placebo-controlled Phase 1 trial with 64 participants across four sequential dosing cohorts, each treated for 28 days and followed for 30 days.

• Doses of 100 mg BID and 200 mg QD were evaluated in Cohorts 1 and 2, with maximal ITK target occupancy at 200 mg and higher.

• Patients had moderate to severe atopic dermatitis, with a high proportion of African American participants and slightly higher baseline EASI in the active group.

• Most patients had prior topical corticosteroid use; some had prior systemic therapies, and most discontinued topical corticosteroids before enrollment.

• Placebo group showed minimal improvement, consistent with literature on lower placebo effects in oral versus injectable trials.